Osphena Approved by FDA to Treat Dyspareunia
Osphena (ospemifene) has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.
Osphena (ospemifene), an estrogen agonist/antagonist with tissue selective effects, has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.
The results of a multicenter, randomized, double-blind, placebo-controlled trial and subsequent safety extension were published online and ahead of print in the journal Menopause. Researchers found that 60 mg of once-daily oral ospemifene was effective in treating of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.1 The one-year, long-term safety extension study found no clinically significant adverse changes, including no clinically meaningful endometrial findings, no treatment-emergent adverse events of pelvic organ prolapse or venous thromboembolism, and no cases of endometrial hyperplasia or carcinoma.2 In both studies, hot flushes were the most common treatment-related adverse event.
References:
1. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jan 28. [Epub ahead of print].
2. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2012 Nov 8. [Epub ahead of print].
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
